Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 4, 2012, Pages 437-443

  Kuhlmann, Jan B ^a   Euringer, Wulf ^a   Spangenberg, Hans C ^a   Breidert, Matthias ^c   Blum, Hubert E ^a   Harder, Jan ^b   Fischer, Richard ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Department of Traumatology   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Biliary tract cancer; Cholangiocarcinoma; Drug eluting beads; Irinotecan; Transarterial chemoembolization

Indexed keywords

GELFOAM; GEMCITABINE; IODINATED POPPYSEED OIL; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLANGITIS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELUTING BEAD; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERTENSION; LEUKOPENIA; LIVER ABSCESS; LIVER FAILURE; MALE; MUCOSA INFLAMMATION; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PLEURA EMPYEMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CAMPTOTHECIN; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; EPIDEMIOLOGIC METHODS; FEMALE; GELATIN SPONGE, ABSORBABLE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; MITOMYCIN; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 84859423842     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283502241     Document Type: Article

References (37)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357. (Pubitemid 32496970)
2. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10-12.
3. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol 2002; 37:806-813. (Pubitemid 35404220)
4. Tan JC, Coburn NG, Baxter NN, Kiss A, Law CH. Surgical management of intrahepatic cholangiocarcinoma - a population-based study. Ann Surg Oncol 2008; 16:277-291.
5. Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surg Oncol 2007; 16:277-291.
6. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15:4240-4262.
7. Mosconi S, Beretta GD, Labianca R, Zampino MG, Gatta G, Heinemann V. Cholangiocarcinoma. Crit Rev Oncol Hematol 2009; 69:259-270.
8. Verslype C, Prenen H, Van Cutsem E. The role of chemotherapy in biliary tract carcinoma. HPB (Oxford) 2008; 10:164-167. (Pubitemid 352016240)
9. Valle J, Wasan H, Palmer DH, Cunnungham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273.
10. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739. (Pubitemid 34607087)
11. Burger I, Hong K, Schuzlick R, Georgiades C, Thuluvath P, Choti M, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16:353-361. (Pubitemid 40354852)
12. Carter S, Martin Ii RC. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (Oxford) 2009; 11:541-550.
13. Hong K, Geschwind JF. Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma. Semin Oncol 2010; 37:110-117.
14. Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, et al. OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009; 32: 1187-1192.
15. Kirchhoff T, Zender L, Merkesdal S, Frericks B, Malek N, Bleck J, et al. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 2005; 11:1091-1095. (Pubitemid 40352992)
16. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101:476-480.
17. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al.; PRECISION V Investigators. Prospective randomized study of doxorubicineluting- bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52.
18. Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release 2006; 116:e55-e56.
19. Taylor RR, Tang Y, Gonzalez MV, Stratford PW, Lewis AL. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007; 30:7-14. (Pubitemid 44908921)
20. Fiorentini G, Aliberti C, Turrisi G, Del Conte A, Rossi S, Benea G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007; 21:1085-1091.
21. Martin RC, Robbins K, Tomalty D, O'Hara R, Bosnjakovic P, Padr R, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009; 7:80.
22. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010; 33:960-966.
23. Feisthammel J, Schoppmeyer K, Mö ssner J, Schulze M, Caca K Wiedmann M. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial. Am J Clin Oncol 2007; 30:319-324. (Pubitemid 46884156)
24. Sanz-Altamira PM, O'Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol 2001; 12:501-504. (Pubitemid 32472105)
25. Sugita H, Hirota M, Ichihara A, Furuhashi S, Kihara S, Shimada S. Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer. J Hepatobiliary Pancreat Surg 2006; 13:463-467. (Pubitemid 44480252)
26. Sun W, Hewitt MR, Theobald MR, Hershock D, Haller DG. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer 2007; 110:2768-2774. (Pubitemid 350250348)
27. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol 2010; 21:1084-1090.
28. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, et al. Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95:848-851.
29. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008; 5:883-888.
30. Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH, et al. Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes. Cancer 2008; 113:1614-1622.
31. Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 2010; 255:270-277.
32. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-551.
33. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S, et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007; 30: 1156-1165. (Pubitemid 350059808)
34. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37:212-220.
35. Tsochatzis EA, Germani G, Burroughs AK. Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment. Semin Oncol 2010; 37:89-93.
36. Tanaka N, Yamakado K, Nakatsuka A, Fujii A, Matsumura K, Takeda K. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma - initial experience. Eur J Radiol 2002; 41:42-48. (Pubitemid 34002989)
37. Vogl TJ, Schwarz W, Eichler K, Hochmuth K, Hammerstingl R, Jacob U, et al. Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol 2006; 132:745-755. (Pubitemid 44337935)